Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.
How did CYYNF's recent EPS compare to expectations?
The most recent EPS for Cynata Therapeutics Limited is $, expectations of $.
How did Cynata Therapeutics Limited CYYNF's revenue perform in the last quarter?
Cynata Therapeutics Limited revenue for the last quarter is $
What is the revenue estimate for Cynata Therapeutics Limited?
According to of Wall street analyst, the revenue estimate of Cynata Therapeutics Limited range from $ to $
What's the earning quality score for Cynata Therapeutics Limited?
Cynata Therapeutics Limited has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Cynata Therapeutics Limited report earnings?
Cynata Therapeutics Limited next earnings report is expected in 2026-05-27
What are Cynata Therapeutics Limited's expected earnings?
Cynata Therapeutics Limited expected earnings is $, according to wall-street analysts.
Did Cynata Therapeutics Limited beat earnings expectations?
Cynata Therapeutics Limited recent earnings of $ expectations.